FGP
CAI

Freestone Grove Partners’s Caris Life Sciences CAI Stock Holding History

Freestone Grove Partners’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.1K Buy
3,655
+3,649
+60,817% +$65.3K ﹤0.01% 860
2026
Q1 		$107 Buy
+6
New +$131 ﹤0.01% 902
2025
Q4 		– Sell
-251,389
Closed -$7.6M – 992
2025
Q3 		$7.6M Buy
251,389
+201,389
+403% +$6.42M 0.06% 313
2025
Q2 		$1.34M Buy
+50,000
New +$1.35M 0.01% 404

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Freestone Grove Partners's CAI Position: Q2 2026 in Review

Freestone Grove Partners increased its Caris Life Sciences (CAI) stake by 60,817% in Q2 2026, buying an estimated $65.3K and bringing the position to 3,655 shares worth $65.1K. The position accounts for ﹤0.01% of the portfolio, ranked #860.

Freestone Grove Partners first reported a position in CAI in Q2 2025 and has held it in 4 quarters since. The position peaked at $7.6M in Q3 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Freestone Grove Partners held 3,655 shares of Caris Life Sciences worth $65.1K as of Q2 2026.
  • Freestone Grove Partners bought 3,649 Caris Life Sciences shares in Q2 2026, an estimated $65.3K.
  • Caris Life Sciences made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #860 holding.
  • Freestone Grove Partners first reported a position in Caris Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • Freestone Grove Partners's Caris Life Sciences position peaked at $7.6M in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.